权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma

SHP2 的致病作用

基本信息

批准号：
9329399
负责人：
Shizhen Zhu
金额：
$ 24.9万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-01 至 2018-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9329399
关键词：
Animals Apoptotic Award Biology Breast Cancer Biology Cell Line Cell Survival Cessation of life Child Childhood China Chronic Communities Coupled DNA DNA Resequencing Dana-Farber Cancer Institute Development Disease Doxycycline Embryo Environment GAB2 gene Genes Genomics Goals Human Institution International Investigation Laboratory Finding Lead MYCN gene Maintenance Malignant Neoplasms Mediator of activation protein Medical Mentors Mentorship Modeling Molecular Abnormality Molecular Target Mosaicism Mutation Myelogenous NTRK1 gene Neuroblastoma Normal tissue morphology Oncogenes PTPN11 gene Pathogenesis Pathogenicity Pathologic Pathway interactions Pediatric Oncology Peripheral Phase Phosphoric Monoester Hydrolases Protein Tyrosine Kinase Protein Tyrosine Phosphatase Proteins Qualifying RNA Research Research Personnel Risk Role Signal Transduction Signaling Molecule Singapore Structure Sympathetic Nervous System System Testing Tissues Toxic effect Training Transgenic Organisms Treatment Failure Tumor Suppressor Genes Tumor Suppressor Proteins Variant Work Zebrafish cancer cell chemotherapy childhood cancer mortality experimental study high risk improved in vivo Model instructor member microdeletion neoplastic cell neuroblastoma cell next generation novel overexpression pediatric department public health relevance response small molecule inhibitor success targeted treatment tumor

项目摘要

DESCRIPTION (provided by applicant): Neuroblastoma, a highly malignant tumor that arises in the peripheral sympathetic nervous system, accounts for ~10% of all cancer-related deaths in children. Recent genomic resequencing of high-risk neuroblastoma has uncovered three main classes of mutations: those activating the ALK tyrosine kinase (8- 10% of cases), those activating the SHP2 phosphatase (2-3%), and microdeletions involving the PTPRD locus (6-10%). I recently demonstrated that activated ALK synergizes with MYCN to induce neuroblastoma in zebrafish by inhibiting a developmentally-timed apoptotic response (Zhu et al, Cancer Cell). I have now discovered that activated SHP2 or Ptprd loss also accelerates MYCN-induced neuroblastoma, but in a different way than does activated ALK. On the advice of my close collaborator, Dr. Ben Neel, an internationally recognized expert on phosphatase biology, I have determined that multiple components of the SHP2 pathway are highly overexpressed in most human neuroblastomas, including GAB2, a known oncogene and SHP2 regulator, as well as ALK and NTRK1. The central hypothesis to be explored here is that SHP2 and PTPRD represent vital pathways to the development of neuroblastoma and warrant further intensive investigation. My key objective is to elucidate the underlying mechanisms by which these two pathways influence neuroblastoma initiation and maintenance. My specific aims are (1) to define the mechanisms by which mutationally activated SHP2 contributes to neuroblastoma initiation and maintenance, and determine whether the SHP2 pathway is aberrantly activated in neuroblastoma cases that lack SHP2 mutations; and (2) to elucidate the mechanisms by which loss of the PTPRD tumor suppressor gene contributes to neuroblastoma initiation and maintenance. In these two Aims, I will use mosaic and stable transgenic as well as structure- function approaches to implicate key downstream pathways and a novel tissue-specific, conditional doxycycline-regulated system to establish whether activated SHP2 or loss of PTPRD is continuously required for tumor cell survival, thus qualifying as "drivers" of neuroblastoma pathogenesis. Dr. Shizhen (Jane) Zhu is an instructor in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI) working under the mentorship of Dr. A. Thomas Look, a pioneer in the field of zebrafish cancer biology. Building on Dr. Zhu's medical and scientific training in China and Singapore, she is now defining the roles of aberrant SHP2 and PTPRD tyrosine phosphatase pathways in the neuroblastoma pathogenesis. Dr. Look's proven mentorship coupled with the rigorous and nurturing scientific environment offered by the research community at DFCI and affiliated institutions offer the maximal opportunity for Dr. Zhu's success during her award period as an instructor and in her transition to become an independent investigator.

描述（由申请人提供）：神经母细胞瘤是一种发生在外周交感神经系统的高度恶性肿瘤，占儿童所有癌症相关死亡的10%。最近对高危神经母细胞瘤的基因组重测序发现了三种主要类型的突变：激活ALK酪氨酸激酶的突变（8- 10%的病例）、激活SHP 2磷酸酶的突变（2-3%）和涉及PTPRD基因座的微缺失（6-10%）。我最近证明了活化的ALK与MYCN协同作用，通过抑制发育定时的凋亡反应诱导斑马鱼中的神经母细胞瘤（Zhu等人，Cancer Cell）。我现在发现，激活的SHP 2或Ptprd丢失也加速MYCN诱导的神经母细胞瘤，但与激活的ALK不同。根据我的密切合作者，国际公认的磷酸酶生物学专家Ben Neel博士的建议，我已经确定SHP 2通路的多个组分在大多数人类神经母细胞瘤中高度过表达，包括GAB 2，一种已知的致癌基因和SHP 2调节剂，以及ALK和NTRK 1。这里要探讨的中心假设是SHP 2和PTPRD代表了神经母细胞瘤发展的重要途径，并需要进一步深入研究。我的主要目标是阐明这两种途径影响神经母细胞瘤发生和维持的潜在机制。我的具体目标是（1）确定突变激活的SHP 2促进神经母细胞瘤发生和维持的机制，并确定SHP 2通路是否在缺乏SHP 2突变的神经母细胞瘤病例中异常激活;（2）阐明PTPRD肿瘤抑制基因缺失促进神经母细胞瘤发生和维持的机制。在这两个目标中，我将使用镶嵌和稳定的转基因以及结构-功能方法来暗示关键的下游途径和新的组织特异性的条件性多西环素调节系统，以确定激活的SHP 2或PTPRD的缺失是否是肿瘤细胞存活所持续需要的，从而有资格作为神经母细胞瘤发病机制的“驱动因素”。朱世珍博士是丹娜-法伯癌症研究所（DFCI）儿童肿瘤科的讲师，在A。托马斯看，斑马鱼癌症生物学领域的先驱。基于朱博士在中国和新加坡的医学和科学培训，她现在正在确定异常SHP 2和PTPRD酪氨酸磷酸酶途径在神经母细胞瘤发病机制中的作用。Look博士经过验证的指导加上DFCI和附属机构研究社区提供的严格和培育的科学环境，为朱博士在获奖期间作为讲师和过渡到独立研究者的成功提供了最大的机会。